Wells Fargo Maintains Equal-Weight on Medline, Lowers Price Target to $34
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Stephen Baxter maintains Medline (NASDAQ:MDLN) with a Equal-Weight and lowers the price target from $45 to $34.
Wells Fargo analyst Stephen Baxter maintains Medline (NASDAQ:MDLN) with a Equal-Weight and lowers the price target from $45 to $34.